pioglitazone has been researched along with Elevated Cholesterol in 13 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In non-diabetic patients with hypertension or hypercholesterolemia, pioglitazone improves insulin sensitivity, lipid profile, and inflammation but does not affect endothelin activity." | 5.19 | PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia. ( Campia, U; Cardillo, C; Matuskey, LA; Panza, JA; Tesauro, M, 2014) |
| "It is well known that patients with type 2 diabetes are more likely to be dyslipidemic than the general population." | 2.48 | Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. ( Ambrosio, ML; Bartoli, N; Mannucci, E; Marchionni, N; Monami, F; Monami, M; Ragghianti, B; Toffanello, G; Vitale, V, 2012) |
| "Obesity is often associated with chronic inflammatory state which contributes to the development of insulin resistance (IR) and type 2 diabetes mellitus (T2DM)." | 1.39 | Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. ( El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Assmann, AK | 1 |
| Winnicki, V | 1 |
| Sugimura, Y | 1 |
| Chekhoeva, A | 1 |
| Barth, M | 1 |
| Assmann, A | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Wang, JM | 1 |
| Wang, D | 1 |
| Tan, YY | 1 |
| Zhao, G | 1 |
| Ji, ZL | 1 |
| Campia, U | 2 |
| Matuskey, LA | 2 |
| Tesauro, M | 1 |
| Cardillo, C | 1 |
| Panza, JA | 2 |
| Wu, ZH | 1 |
| Zhao, SP | 1 |
| Chu, LX | 1 |
| Ye, HJ | 1 |
| Mourad, AA | 1 |
| Heeba, GH | 1 |
| Taye, A | 1 |
| El-Moselhy, MA | 1 |
| Monami, M | 1 |
| Vitale, V | 1 |
| Ambrosio, ML | 1 |
| Bartoli, N | 1 |
| Toffanello, G | 1 |
| Ragghianti, B | 1 |
| Monami, F | 1 |
| Marchionni, N | 1 |
| Mannucci, E | 1 |
| Chu, Y | 1 |
| Lund, DD | 1 |
| Weiss, RM | 1 |
| Brooks, RM | 1 |
| Doshi, H | 1 |
| Hajj, GP | 1 |
| Sigmund, CD | 1 |
| Heistad, DD | 1 |
| Moroe, H | 1 |
| Fujii, H | 1 |
| Honda, H | 2 |
| Arai, K | 1 |
| Kanazawa, M | 1 |
| Notoya, Y | 2 |
| Kogo, H | 1 |
| Taniguchi, J | 1 |
| Shibusawa, Y | 1 |
| Iwata, T | 1 |
| Heine, RJ | 1 |
| Pakala, R | 1 |
| Dilcher, C | 1 |
| Baffour, R | 1 |
| Hellinga, D | 1 |
| Seabron, R | 1 |
| Joner, M | 1 |
| Kolodgie, F | 1 |
| Virmani, R | 1 |
| Waksman, R | 1 |
| Omasu, F | 1 |
| Oda, T | 1 |
| Yamada, M | 1 |
| Yoshizawa, N | 1 |
| Yamakami, K | 1 |
| Sakurai, Y | 1 |
| Miura, S | 1 |
| Barac, A | 1 |
| Lu, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pioglitazone Treatment in Patient's Calcific Aortic Valve Disease With Mild Aortic Valve Stenosis[NCT05875675] | Phase 2 | 100 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Elevated Cholesterol
| Article | Year |
|---|---|
Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Topics: Acarbose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inh | 2012 |
2 trials available for pioglitazone and Elevated Cholesterol
| Article | Year |
|---|---|
PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia.
Topics: Biomarkers; C-Reactive Protein; Cross-Over Studies; District of Columbia; Double-Blind Method; Endot | 2014 |
Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Topics: Adipokines; Adiponectin; Adult; Aged; Case-Control Studies; Cross-Over Studies; Double-Blind Method; | 2008 |
10 other studies available for pioglitazone and Elevated Cholesterol
| Article | Year |
|---|---|
Impact of PPAR-gamma activation on the durability of biological heart valve prostheses in hypercholesterolaemic rats.
Topics: Animals; Heart Valve Prosthesis; Hypercholesterolemia; Hyperplasia; Obesity; Pioglitazone; PPAR gamm | 2022 |
22(R)-hydroxycholesterol and pioglitazone synergistically decrease cholesterol ester via the PPARγ-LXRα-ABCA1 pathway in cholesterosis of the gallbladder.
Topics: ATP Binding Cassette Transporter 1; Cells, Cultured; Cholesterol Esters; Drug Synergism; Epithelial | 2014 |
Pioglitazone reduces tumor necrosis factor-alpha serum concentration and mRNA expression of adipose tissue in hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Cholesterol, Dietary; Cholesterol, | 2010 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, | 2013 |
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia.
Topics: Adiponectin; Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; Apolipoprotein B-100; Apoptosis; B | 2013 |
Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery.
Topics: Animals; Biological Factors; Charybdotoxin; Endothelium, Vascular; Enzyme Inhibitors; Hypercholester | 2004 |
Alteration in endothelial function and modulation by treatment with pioglitazone in rabbit renal artery from short-term hypercholesterolemia.
Topics: Acetylcholine; Animals; Biological Factors; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme Inhib | 2005 |
[Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; | 2006 |
Peroxisome proliferator-activated receptor gamma ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit.
Topics: Actins; Administration, Oral; Animals; Body Weight; Catheterization; Cholesterol, Dietary; Hyperchol | 2006 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2007 |